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A Randomized Controlled Crossover Study
ELODIE BOUSQUET, MD,*† TALAL BEYDOUN, MD,* PIERRE-RAPHAËL ROTHSCHILD, MD,*†
CIARA BERGIN, PHD,‡ MIN ZHAO, MD, PHD,† RUI BATISTA, PHARMD,§
MARIE-LAURE BRANDELY, PHARMD,§ BENEDICTE COURAUD,* NICOLETTE FARMAN, MD, PHD,¶
ALAIN GAUDRIC, MD, PHD,** FRANÇOIS CHAST, PHARMD, PHD,§
FRANCINE BEHAR-COHEN, MD, PHD†‡
Purpose: To evaluate the effect of spironolactone, a mineralocorticoid receptor
antagonist, for nonresolving central serous chorioretinopathy.
Methods: This is a prospective, randomized, double-blinded, placebo-controlled cross-
over study. Sixteen eyes of 16 patients with central serous chorioretinopathy and persistent
subretinal ﬂuid (SRF) for at least 3 months were enrolled. Patients were randomized to receive
either spironolactone 50 mg or placebo once a day for 30 days, followed by a washout period
of 1 week and then crossed over to either placebo or spironolactone for another 30 days. The
primary outcome measure was the changes from baseline in SRF thickness at the apex of the
serous retinal detachment. Secondary outcomes included subfoveal choroidal thickness and
the ETDRS best-corrected visual acuity.
Results: The mean duration of central serous chorioretinopathy before enrollment in
study eyes was 10 ± 16.9 months. Crossover data analysis showed a statistically signiﬁcant
reduction in SRF in spironolactone treated eyes as compared with the same eyes under
placebo (P = 0.04). Secondary analysis on the ﬁrst period (Day 0–Day 30) showed a signif-
icant reduction in subfoveal choroidal thickness in treated eyes as compared with placebo
(P = 0.02). No signiﬁcant changes were observed in the best-corrected visual acuity. There
were no complications related to treatment observed.
Conclusion: In eyes with persistent SRF due to central serous chorioretinopathy,
spironolactone signiﬁcantly reduced both the SRF and the subfoveal choroidal thickness as
compared with placebo.
RETINA 35:2505–2515, 2015
Central serous chorioretinopathy (CSC) incidence isestimated at 1 per 10,000,1 affecting predominantly
men (72–88%).2,3 Central serous chorioretinopathy is
considered chronic when subretinal ﬂuid (SRF) does
not reabsorb spontaneously and/or if multifocal recur-
rent detachments with diffuse retinal pigment epithe-
lium (RPE) alterations are observed.4 Chronic CSC
has been shown to severely impact vision. Choroidal
thickness varies as a function of age, axial length, and
circadian rhythm.5 In patients with CSC, pachychoroid
(a thick choroid)6 has been reported not only in the
affected eye but also in the fellow eye,7 which is con-
sistent with bilateral choroidal hyperpermeability.8,9
Corticosteroids, that are produced endoge-
nously10 or that are delivered as therapeutic agents,
have been shown to promote the occurrence and
aggravate CSC,11,12 suggesting that corticoid
metabolism may be involved in the disease patho-
genicity. On binding to the glucocorticoid receptor
or to the mineralocorticoid receptor (MR), gluco-
corticoids exert different effects. Preclinical studies
have shown in the retina and choroid, that the glu-
cocorticoid receptor, MR, and HSD-2 (hydroxyste-
roid dehydrogenase Type 2) are coexpressed.13,14
Therefore, glucocorticoid-induced effects may
result in part from MR activation in the retina and
choroid. Indeed, the activation of MR pathway in
rodents with its speciﬁc ligand aldosterone or fol-
lowing high dose of glucocorticoids resulted in cho-
roid vessel dilation and leakage, effects that were
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shown to be reversible with MR antagonists.14 Our
group has previously identiﬁed a molecular target
for MR activation in the choroid, namely KCa2.3,
which is an endothelial hyperpolarizing calcium-
dependent potassium channel involved in vasore-
laxation. Mineralocorticoid receptor antagonist
reversed the upregulation of KCa2.3 in the choroid
demonstrating its local molecular action.14 Our
hypothesis is that excessive occupancy of MR by
glucocorticoids and/or excessive MR sensitivity or
endogenous activation may increase choroidal
thickness and susceptibility to CSC.
Different MR antagonists are available in the market
and have been approved for congestive heart failure
and for primary hyperaldosteronism. Spironolactone,
the oldest drug of this class, can exert hormonal effects
at high dose and with prolonged use (.3 months),
including gynecomastia, reduced libido, and menstrual
disturbance.15 Eplerenone, with an increased speciﬁc-
ity does not induce hormonal effects but has in vivo
a 50-fold reduced efﬁcacy on MR blockage.16 In a pre-
vious prospective pilot but uncontrolled study, we
treated 13 patients with CSC for 3 months with oral
eplerenone. The results showed a signiﬁcant treatment
effect on SRF and central macular thickness.17 Epler-
enone is not available as a medical grade pure sub-
stance, such that treatment and placebo can be
manufactured in identical galenic formulation, as is
required to conduct a controlled, double-masked pro-
spective study; therefore, spironolactone was chosen
for this investigation.
This study set out to evaluate the clinical effect of
the MR-antagonist spironolactone in a prospective,




Eligibility criteria included the following: 1) pa-
tients aged $18 and #70 years; 2) patients with the
best-corrected visual acuity between 20/200 and
20/32; 3) SRF involving the fovea on optical coher-
ence tomography (OCT); 4) the presence of angio-
graphic leakage caused by CSC on ﬂuorescein
angiography; 5) visual symptoms and OCT follow-
up consistent with CSC for more than 3 months of
duration with no spontaneous reduction of SRF
(proven on an OCT at least 3 months before entering
the study); and 6) women included were required to
use oral contraception during the study. Exclusion cri-
teria disqualiﬁed the following subjects: 1) previous
treatment with photodynamic therapy or anti-VEGF
intravitreal injection; 2) any evidence of choroidal
neovascularization, polypoidal choroidal vasculop-
athy, or pseudo vitelliform lesions; 3) history of other
macular abnormalities; 4) systemic contraindication
for spironolactone treatment: liver or kidney failure,
hyperkaliema .5.5 mmol/L, 5) treatment with non
steroidal anti-inﬂammatory or concomitant drugs that
increase potassium level; 6) known allergy to the study
drug or to lactose or to ﬂuorescein; and 7) pregnancy.
Study Design
This was a prospective, double-blinded, randomized
placebo-controlled crossover study. From January
2012 to October 2012, 16 patients who met the
inclusion criteria and consented to partake in the study
were enrolled from the Ophthalmology Department of
Hôtel Dieu of Paris Hospital, France.
Ethics Statement
Written informed consent was obtained from all
participants. This study was approved by the Paris
Centre Ethical Committee on January 7, 2012. It was
declared and authorized by AFSSAPS (Food and Drug
Administration in France) under identiﬁcation number
# 2011-003046-40a and declared on Clinical Trials.
gov Identiﬁer under # NCT01552044 (February 14,
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2012). The study was conducted in accordance with
the tenets of the Declaration of Helsinki. INSERM (the
National Institute for Health and Research in France)
has promoted and monitored this study.
Study Drug
Spironolactone is a steroid with a strong antagonist
effect on the MR. At the dosage of 50 mg/day for 30
days utilized within this study protocol, spironolactone
is not expected to induce any signiﬁcant effect on blood
pressure nor androgenic or progesterone receptor
interference.18 Tablets containing either the treatment
drug of 50 mg spironolactone (Piramal Healthcare
UK), or placebo tablet (comprised of lactose) were
administered orally during the study period. Tablets
had identical galenic presentation; these were prepared
by the Department of Pharmacy of Hôtel-Dieu of Paris
Hospital.
Study Protocol
After signing the informed consent, each patient was
randomized to one of the two treatment sequences:
sequence treatment/placebo (TP) or sequence placebo/
treatment (PT). Sequence TP was where patients
received spironolactone 50 mg/day for 30 days, then
a washout period, where no treatment was adminis-
tered for 7 days, followed by placebo for 30 days. In
the treatment sequence, PT patients received placebo
for 30 days, then a washout period for 7 days,
followed by spironolactone 50 mg/day for a further
30 days. The duration of the washout period was
calculated taking into account that after oral adminis-
tration, the mean post–steady-state half-life for spiro-
nolactone and its active metabolites are 1.4 hours and
16 hours (for spironolactone and canrenone, respec-
tively).19 After 112 hours, 4.6 days (which corre-
sponds to 7 half-lives), no active spironolactone or
active metabolites should be measurable.
The primary end point is reduction in SRF. Based
on pilot data, the treatment effect was estimated to be
70 mm on average.17 The repeatability of measures on
SRF has been estimated to be 30 mm. The power
calculation was based on the ﬁrst period of this study
(i.e., a parallel study design and two-sample t-test). To
have 95% power of detecting a reduction in SRF of
40% (at a statistically signiﬁcant level of a = 5%)
between the TP and PT sequences after the ﬁrst treat-
ment period, 7 patients are required in each group.
Allowing for a 10% dropout during follow-up, a total
of 16 patients were required. The crossover design has
greater power than a parallel design, since each patient
acts as their own control. Therefore, 16 patients were
sufﬁcient here also.
Randomization of treatment sequence, placebo
followed by treatment (PT) or treatment followed
by placebo (TP), was assigned by the pharmacist. The
randomization was done using online statistical
computing web programming (www.graphpad.com/
quickcalcs or www.randomization.com) to generate
the randomization schedule. The labels providing the
batch number were placed by the pharmacist and were
in line with the Commission Directive 2003/94/EC.
Detail of the sequence remained unknown to all mem-
bers of the trial team until recruitment, data collection,
and analysis were complete.
Baseline and Follow-up Examinations
At Day 0 (D0), the end of the ﬁrst period (D30) and
the second period (D67), the best-corrected visual acu-
ity using the Early Treatment Diabetic Retinopathy
Study charts at 4 m (by certiﬁed orthoptist), indocya-
nin and ﬂuorescein angiography (Heidelberg HRA;
Heidelberg Engineering, Heidelberg, Germany), and
spectral domain optical coherence tomography
(SD-OCT, Spectralis v5.4.7.0; Heidelberg Engineer-
ing). Angiography and spectral domain OCT using
the Spectralis device were performed at Lariboisière
hospital (where this device was available) by certiﬁed
technicians under A. Gaudric supervision. In addition,
SD-OCT (OPKO/OTI, Miami, FL) was also per-
formed at D
−7 (screening), D0 (inclusion), D30, D37,
and D67 at Hôtel-Dieu by a certiﬁed technician.
Treatment tolerance was assessed by blood pressure
measurements, blood analyses (kaliemia, natremia and
creatinine), performed at the study entry, D30 and D67.
The treatment was to be stopped in case of kaliemia
increase (.5 mmol/L) or creatinine clearance rate
decrease (,60 mL/minute).
Spectralis Spectral Domain Optical Coherence
Tomography Acquisition and Analysis
The scanning protocol included a volume scan
centered on the fovea and comprising 25 horizontal
B-scans, 240 mm apart covering a 20° · 20° ﬁeld.
Each B-scan resulted from 11 averaged images. Image
analysis was then performed using the commercially
available Heidelberg Eye explorer software version
1.7.1.0 (Heidelberg Engineering). The automated seg-
mentation algorithm delineates the internal limiting
membrane and the RPE-Bruch layer. The “retinal
thickness map” mode was used to center the scan on
the point of maximum retinal thickness from baseline
images corresponding to the apex of the subretinal
detachment (Figure 1A). We collected the automati-
cally generated point center thickness. The upper seg-
mentation line was manually adjusted by 2 trained
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operators (E.B. and P.-R.R.) to delineate the external
limiting membrane (Figure 1, B and C) in 5 B scan
using the methodology as described by Tan et al.20
The SRF thickness was automatically generated by
the software after segmentation. Measures from the
external limiting membrane to the Bruch layer integra-
tes both SRF and outer segment length and avoiding
over estimation of SRF reduction due to outer segment
elongation, observed in long-lasting CSC.
Choroid thickness, deﬁned as the distance separat-
ing the outer border of the RPE from the hyper-
reﬂective inner surface of the sclera (lamina fusca) can
be reproducibly measured using enhanced depth
imaging.21 Cross line scans of 30°, composed of 100
averaged images, across the fovea, were obtained auto-
matically. The procedure was repeated until acceptable
quality was achieved. Choroidal thickness was mea-
sured at the fovea and at 500 mm nasally and tempo-
rally from the fovea.
OPKO Spectral Domain Optical Coherence
Tomography Acquisition and Analysis
All subjects included in the study underwent study
measurements by using an OPKO spectral domain
OCT/SLO instrument (OPKO Instrumentations). The
system provides up to 27,000 A-scans per second with
a 5-mm axial resolution. We used the radial lines
acquisition protocol after centering the scans on the
fovea. Manual measure was performed using the cal-
iper tool from the external limiting membrane to the
Bruch layer at the top of SRD by two independent
ophthalmologists (F.B.-C. and E.B.). The measures
of the two operators were compared if there was a dis-
crepancy of greater than 5%, then the measures were
recalculated by both operators. The average of the two
measures was used for in the analysis.
Main Outcome Measures
The primary outcome measure was the change from
baseline in SRF thickness (external limiting membrane
to Bruch layer) at the apex of the subretinal detach-
ment evaluated as described above using the Spectralis
SD-OCT device.
Secondary outcome measures included change from
baseline in SRF thickness evaluated by OPKO SD-
OCT, subfoveal, 500 mm temporal and nasal choroidal
thickness as measured on enhanced depth imaging
Spectralis SD-OCT and best-corrected visual acuity.
Statistical Analysis
The crossover data were analyzed using the linear
mixed ﬁxed-effects model framework. Linear mixed
ﬁxed-effects model assumptions (covariance matrix
structure, normal distribution of random effects, and
residuals) were checked before analysis, using graph-
ical methods and appropriate tests: usual normality
tests on random effects and residuals and testing
variance–covariance matrix structures. In the cross-
over trial, since each patient acts as their own control,
patient heterogeneity is addressed. For the primary
analysis, an analysis of variance table was calculated
on the ﬁtted model. The ﬁtted model was the standard
model with treatment, and period effects examined as
covariants.
The linear model used to analyze the Spectralis
SD-OCT data is given in Equation 1. The covariants
are given explicitly below. The baseline measure at D0
was used to recover degrees of freedom for error by
adjusting the of estimate within-patient variance as
described by Senn (i.e., baseline measures are used
to update the estimate of the variability used in the
model).22 X denotes the ocular characteristic exam-
ined, for example, SRF; treatment (TTT) was none,
placebo, or spironolactone; period was D0, D30, or D67.
X  IDþ TTTþ Period: (1)
From the OPKO SD-OCT data, a second baseline
measure for SRF was available after the washout
period, at D37. With these data, a baseline measurement
was available for all end point measures and as such
Fig. 1. OCT segmentation. A.
ETDRS grid center displaced at
the apex of the DSR. B. OCT
image without segmentation. C.
OCT image with segmentation
at the level of inner limiting
membrane, external limiting
membrane and RPE.
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could be added to the analysis as a covariant to better
estimate the within-patient variance (i.e., account for
individual trends improving/worsening of the eye due
to period not related to treatment).22 Therefore, a differ-
ent linear model was examined (Equation 2): X denotes
the ocular characteristic examined; treatment (TTT0):
placebo or spironolactone; period D30 or D67; and the
baseline of the ocular parameter examined (Bx): base-
line at D0 or baseline at D37.
X  IDþ TTT0 þ Period0 þ Bx: (2)
A secondary analysis considering only the ﬁrst period
was performed, measures on the relative difference
between D0 and D30 were used in the analysis to
account for patient heterogeneity. These differences
were compared between the placebo and the treated
groups, using Student’s t-test or Mann–Whitney test,
according to the results of the normality tests. Differ-
ence between the 2 groups was considered signiﬁcant




Sixteen eyes of 16 patients met the screening criteria
for this study. One patient in the study underwent
a dramatic reduction of SRF before Day 0, (Patient 4,
SRF 485 mm at D
−90, 450 mm at D−7, 125 mm at D0);
therefore, this patient no longer fulﬁlled the inclusion
criteria and was excluded before commencing this trial;
the analysis of data from 15 patients are reported, 8
patients in the TP sequence and 7 in the PT sequence.
Nine patients had bilateral disease and 14 patients
had multiple RPE alterations in at least one eye. In all
bilateral cases, only one eye met the inclusion criteria.
Characteristics of the study eyes are summarized in
Table 1. The mean duration of CSC before enrollment
in study eyes was 10 ± 16.9 months. The mean age of
the patients was 46.5 ± 8 years (range, 37–58 years)
and 80% were male. Five patients (33.3%) reported
a history of steroid intake. The mean SRF thickness at
the top of SRD was 344 ± 103 mm, and the mean sub-
foveal choroidal thickness (SFCT) was 417 ± 117 mm.
There was no statistical difference in patient baseline
characteristics between the 2 groups (Table 1). However,
both SFCT and temporal thickness at 500 mm were
borderline signiﬁcant (P = 0.07; Table 1).
Crossover Analysis Using Spectralis Spectral
Domain Optical Coherence Tomography Data
Crossover analysis showed that there were no
signiﬁcant period effect (P = 0.31; Table 2), whereas
there was a signiﬁcant treatment effect observed (P =
0.04) with respect to reduction in SRF thickness,
showing the signiﬁcant effect of spironolactone as
compared with placebo. Figure 2A shows the compar-
isons of SRF changes (from Spectralis data) in the 2
sequence treatment groups and during the 2 periods
(Months 1 and 2) and the clear crossing effect between
the 2 periods (Months 1 and 2). Although there was
a signiﬁcant treatment effect observed on choroidal thick-
ness parameters (P = 0.01 nasal 500 mm), there was also
a signiﬁcant period and carryover effect observed on (P =
0.04, carryover effect SFCT; P = 0.03; period effect
temporal 500 mm choroidal thickness).
First Period Analysis
Since there was evidence of some carryover effects
on choroidal thickness in the crossover analysis,
supplementary analysis of the ﬁrst period has also been
Table 1. Baseline Characteristics of the Study Population
Baseline Characteristics Full Group (n = 15) TP Sequence (n = 8) PT Sequence (n = 7) P-value
Gender, males (%) 12 (80) 7 (87.5) 5 (71.4) 0.6*
Age, mean (±SD) years 46.5 (±8) 48 (±8.9) 44.7 (±6.4) 0.5**
Previous steroids, n (%) 5 (33.3) 3 (37.5) 2 (28.6) 1*
Duration symptoms, mean (±SD) month 10 (±16.9) 12.3 (±22.6) 7.4 (±4.1) 0.4*
Visual acuity ETDRS, mean (±SD) letter 73.7 (±9.8) 74.3 (±10.9) 73.1 (±9.4) 0.8***
OCT Spectralis baseline measures
SRF ELM-Bruch thickness, mm 344 (±103) 348 (±125) 340 (±87) 0.88**
SFCT, mm 417 (±117) 358 (±67) 468 (±131) 0.07**
500 mm nasal choroid thickness, mm 412 (±110) 372 (±89) 447 (±120) 0.20**
500 mm temporal choroid thickness, mm 404 (±115) 348 (±62) 453 (±131) 0.07**
OCT OPKO baseline measures
SRF thickness, mm 348 (±101) 349 (±100) 348 (±112) 0.99**
Macular thickness, mm3 9.9 (±1.9) 9.8 (±1.2) 9.9 (±2.5) 0.98
ETDRS, Early Treatment Diabetic Retinopathy Study; ELM, external limiting membrane.
*Fisher’s exact test, **student t-test, ***Wilcoxon non-paired test.
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reported. A signiﬁcant reduction in the SFCT was
observed in the treatment group, where SFCT reduced
by 6% in the TP sequence while it increased by 4% in
the TP sequence (P , 0.02, Figure 2C; Table 3).
In addition, a ﬁrst period analysis was also performed
on SRF thickness as measured on Spectralis and on
OPKO devices. As shown on Table 3, the SRF thick-
ness was signiﬁcantly reduced in the TP as compared
with the PT with more than 30% of change from
baseline.
Crossover Analysis on Additional Time Point
Measures Using OPKO Spectral Domain Optical
Coherence Tomography Data
No carryover effects were observed in the SRF
measures as measured with the OPKO OCT device.
The crossover analysis on OPKO data conﬁrmed the
results observed in the Spectralis measurements dem-
onstrating no signiﬁcant period effect (P = 0.41;
Table 2) in the presence of a signiﬁcant treatment
effect (P = 0.04) with respect to the reduction in
SRF. Figure 2B represents the comparison of SRF
changes (from OPKO data) in the 2 sequence treatment
groups and during the 2 periods and the clear crossing
effect between the 2 periods (Months 1 and 2).
Visual Acuity Analysis
The median ETDRS BVCA at baseline was 76
letters with an interquartile range of 71 to 81 letters.
The treatment did improve the best-corrected visual
acuity in the TP sequence after the ﬁrst period (74.2
letters at D0, 77.4 letters at D30), whereas the PT
sequence showed no change (73.1 letters at D0, 72.6
at D30), but this improvement did not reach statistical
signiﬁcance (P . 0.30) (Table 3). Directly after treat-
ment in both sequences (D30 in the TP sequence and
D67 in the PT sequence), median ETDRS BVCA
increased to 78 letters with an interquartile range of
74 to 80 letters. This was not a statistically signiﬁcant
difference (P = 0.48, paired Wilcoxon’s test).
Angiographic and Optical Coherence
Tomography Findings
Most patients followed the expected treatment
trajectories of switch on response to treatment and
the switch off response when treatment was stopped.
The majority of eyes (67%; 10/15) experienced
a reduction in both retinal and choroidal thickness












Sub foveal ,0.01 0.06
Nasal 500 mm ,0.02 0.87





ELM, external limiting membrane; ILM, inner limiting
membrane.
Fig. 2. A. Relative changes in SRF thickness measured from external limiting membrane (ELM) to Bruch membrane with Spectralis OCT. The
spironolactone effect was signiﬁcant against placebo (P = 0.04). B. Relative changes in SRF thickness measured from ELM to Bruch membrane with
OPKO OCT. The signiﬁcant treatment effect is conﬁrmed (P = 0.049). C. Relative changes in choroidal thickness during the ﬁrst period. A signiﬁcant
decrease of SFCT is observed in spironolactone group as compared with placebo group (P = 0.02). For each group, at each time point, the data have
been summarized using box and whisker plots, the upper and lower 95% CIs (conﬁdence interval) are marked with the whiskers, the box represents the
interquartile range, and the median is represented by the bold horizontal line bisecting the box.
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when under treatment (TP sequence at D30 5/8eyes; PT
sequence at D67 5/7eyes).
In the Sequence Treatment/Placebo
The immediate on–off effect of the treatment was
observed in four of the eight patients in this sequence.
An example of this was Patient 1, this patient presented
with CSC 6 months after their primary episode, this
second episode showed no resolution of SRF for 4
months (Figure 3A). After 30 days of spironolactone
(M1), SRF had completely resolved (Figure 3B), how-
ever, after switching to placebo for 30 days, the SRF had
reformed presenting with increased ﬂuorescein leakage
at the initial RPE leak site (Figure 3C). The off effect
can be disguised by a carryover effect; this was observed
in three patients. For example Patient 6 presented with
bilateral disease as shown on autoﬂuorescent images
(Figure 4A) and 2 active RPE leaks were observed
(Figure 4B). Central serous chorioretinopathy persisted
for 3.5 months before enrollment here after 30 days of
spironolactone, SFCT decreased from 610 mm to
548 mm and SRF had largely resolved with some seg-
ments remaining elongated (Figure 4, B and C). The
following while under placebo, the anatomical structure
of the fovea continued to normalize although SFCT
returned to 608 mm (Figure 4D).
In the Sequence Placebo/Treatment
The ﬁve of the seven of eyes in the PT sequence
showed the expected off/on response. Patient 8 for
example presented with history of CSC episodes in
both eyes and a persistent CSC for more than 6 months
with a faint RPE leak (Figure 5A). Under the
ﬁrst placebo period, no change was observed
(Figure 5B), followed by a signiﬁcant improvement
on D67 after 1 month of spironolactone, with reduction
Table 3. First Period Analysis
Mean Change From
Baseline
Mean % Change From
Baseline
P-value: Wilcoxon Nonpaired TestPT TP PT TP
Spectralis data
SRF ELM-Bruch thickness, mm −10.29 −101.50 −3.9 −34.5 ,0.05
Choroidal thickness, mm
Sub foveal 13.9 −28.6 3.8 −5.5 ,0.02
Nasal 500 mm −4.7 −18.9 −0.2 −4.3 .0.26
Temporal 500 mm 3.7 −17.0 0.2 −3.5 .0.16
OPKO data
SRF ELM-Bruch thickness, mm −18.57 −136.25 −0.8 −38.2 ,0.03
Visual acuity measures
BCVA (increase in letters) −0.6 3.14 −0.6 4.7% .0.30
ELM, external limiting membrane.
Fig. 3. Patient 1 treated ﬁrst by
spironolactone and presented
a decrease of SRF at 1 month as
compared with Day 0 (A and B).
After a 7-day washout period, he
was treated during 1 month by
placebo and the SRF increased
(C). For each time point, ﬂuo-
rescein angiography images
taken at late stage (5 minutes)
(left panel) are shown, together
with the ETDRS grid (middle
panel) and an enhanced depth
imaging scan (right panel).
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of both SRF and leakage on ﬂuorescein angiography
(Figure 5C); likewise, subfoveal thickness did not
change from D0 to D30 (460 mm to 464 mm) but
decreased after 30 days of spironolactone treatment
(D67 = 419 mm). There were 2 eyes, in which placebo
treatment coincided with a large reduction of SRF, so
while the choroidal thickness reduced in these eyes
during D67, the retinal thickness increased marginally.
Patient 2 is one of the 3 women of the study,
presenting with a long lasting CSC (.1 year) and
several RPE leaky points (Figure 6A). She
showed minimal improvement under placebo at M1
(Figure 6B) and slight SRF increase after 1 month of
spironolactone treatment (Figure 6C). She is representa-
tive of absence of response to treatment as observed in
another patient of the study.
Safety
None of the patients experienced any severe side
effects from the treatment; in particular, no protocol
violations occurred due to adverse side effect, as blood
Fig. 4. Follow-up of Patient 6
treated with spironolactone on
the ﬁrst period. Autoﬂuorescent
images of both eyes show
bilateral disease (A). After 1
month of spironolactone, the
SRF almost completely resolved
and decreased intensity of focal
leaks was observed on ﬂuores-
cein angiography (B and C).
Under placebo for a month,
retinal detachment completely
resolved (D). For each time
point, ﬂuorescein angiography
images taken at late stage
(5 minutes) (left panel) are
shown, together with the
ETDRS grid (middle panel) and
an enhanced depth imaging scan
(right panel).
Fig. 5. Follow-up of Patient 8
treated with placebo on the ﬁrst
period. Under the ﬁrst placebo
period, no change was observed
(A and B), followed by a signif-
icant improvement on D67 after
1 month of spironolactone, with
reduction of SRF and leakage
on ﬂuorescein angiography (C).
For each time point, ﬂuorescein
angiography images taken at
late stage (5 minutes) (left
panel) are shown, together with
the ETDRS grid (middle panel)
and an enhanced depth imaging
scan (right panel).
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pressure and blood analyses (kaliemia and creatinine
clearance) remained in the normal range for all
patients.
Discussion
Although several medical treatments have been
proposed for persistent CSC,24,25 very few controlled
studies have evaluated medical treatment modalities
for this condition. Based on the observed association
of CSC with corticosteroid exposure, mifepristone,
a speciﬁc glucocorticoid antagonist has been evaluated
for 12 weeks against placebo and showed potential
effects but with a low tolerance.26 Taking into account
the high endogenous ﬂuctuation of this disease and the
strong psychological impact in its evolution, it is clear
that no beneﬁt of a medical treatment can be estab-
lished without a placebo-controlled study. Having pre-
viously found encouraging results with oral
eplerenone on persistent SRF in patient with CSC,17
the purpose of this study was to evaluate the effect of
another MR antagonist spironolactone administered
orally, against placebo on SRF in nonresolving CSC.
This study was designed to evaluate the optimal treat-
ment conditions (regimen, duration, dose) but provide
evidence of the potential biological effect of MR
antagonist on SRF. The crossover study design to re-
duces confounding covariates because each crossover
patient serves as his or her own control.
The results demonstrated a signiﬁcant reduction of
SRF in treated eyes. The analysis on retinal thickness
and SRF on measures taken with the two SD-OCT
devices, Spectralis and OPKO devices, detected no
signiﬁcant carryover or period effects in the presence
of a statistically signiﬁcant treatment effect on SRF.
However, there were signiﬁcant carryover effects
observed in choroidal thickness. In the presence of
these carryover effects, a subanalysis of the data from
only the ﬁrst period (D0–D30) of this trial (similar to
a randomized, double blinded, parallel clinical trial)
reafﬁrmed the signiﬁcant treatment effect of spirono-
lactone on SFCT, SRF, and retinal thickness.
The pharmacokinetics of spironolactone and its
active metabolites (canrenone) showed that the treat-
ment drug had a half-live inferior to 7 hours.27 Given
the 7-day washout period used here, the signiﬁcant
carryover effects observed in choroidal thickness can-
not be attributed directly to the active drug. These
carryover effects may be due to secondary biological
events after spironolactone treatment. As such, future
studies should consider such possible biological ef-
fects in terms of study design. In addition, there was
a borderline signiﬁcant difference observed in the
baselines measures of choroidal thickness between
the TP sequence and the PT sequence groups. This
may have contributed to the observed carryover effect.
A larger sample would have reduced the likelihood of
such an imbalance occurring in a randomized trial.
The available data indicates that other contributory
factors could induce RPE leaks; since in most study
patients, both eyes presented with a dilated choroid yet
CSC was monocular. Whether MR antagonists have
an effect on these possible additional factors remains
to be explored. In the ﬁeld of vascular diseases,
MR overactivation is a recognized pathogenic
factor mediating endothelial dysfunction, vascular
inﬂammation, and remodeling; furthermore, it is
Fig. 6. Follow-up of Patient 2,
treated with placebo on the ﬁrst
period. She showed a decrease
of SRF under placebo at D30
(A and B) and a slight SRF
increase after 1 month of spi-
ronolactone treatment (C). For
each time point, ﬂuorescein
angiography images taken at late
stage (5 minutes) (left panel) are
shown, together with the
ETDRS grid (middle panel) and
an enhanced depth imaging scan
(right panel).
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recognized that MR antagonists reverse these effects.28
In our experimental studies, we have identiﬁed
KCa2.3 as a potential molecular target of MR activa-
tion in the choroid. There are other potential molecular
targets that are regulated by MR/glucocorticoid recep-
tor complexes, and there may be additional potential
therapeutic pathways.
The trial design and the short treatment period were
chosen to further demonstrate the treatment effect
since recurrence after treatment withdrawal is also
supportive evidence. Clinically, the strong recurrence
observed in some cases after 1 month of treatment
indicates that either more prolonged use or ongoing
treatment is required to maintain the absence of SRF in
these eyes. However, since the MR antagonists used
have low toxicity and tolerable adverse side effects,
prolonged use of these treatments should not be
a limiting factor.
No statistically signiﬁcant changes were observed in
the visual acuity, this is likely related to the small
sample size (a sample of.100 eyes would be required
to detect a change of 3 letters between the groups) and
limitations on achievable visual acuity recovery due to
the high baseline BVCA (.70 letters in 12 of the 15
cases enrolled).
The optimal dose or duration of spironolactone
required to treat the patient will be the subject
of further study. Recent preclinical studies have
indicated that females are less sensitive to the
effects of spironolactone than men, and that there are
racial differences in spironolactone sensitivity (with
Afro-American being less sensitive),28,29 which indi-
cates that further dose–response studies are required.
Also, since spironolactone is a target of efﬂux protein,
its ocular penetration might therefore be reduced when
outer retinal barrier is restored, suggesting that oral
administration may not be optimal for long-term treat-
ment therefore, alternative delivery pathways also
require investigation.
The limitations of this study are the nonoptimal
dosage per patient, the small sample size, the short
treatment period, and the unforeseen carryover effect
in choroidal thickness from M1 into M2. The non-
optimal dosage per patient may be correlated with the
different treatment response observed between patients
and with reduced efﬁcacy. The short treatment period
may have limited the treatment efﬁcacy in patients
with more advanced/prolonged disease. The estima-
tion of the washout period was based on the half-life of
the drug; however, since signiﬁcant carryover effects
were observed in choroidal thickness of these patients,
this would suggest that the washout period was not
sufﬁcient to study this parameter using the crossover
design. Future studies should select more restricted
phenotypic characteristics in addition to SRF duration
to study a more homogenous population.
Although very large sample sizes are required to
demonstrate equivalence (less than 5% difference) on
parameters with poor repeatability (e.g., visual acuity),
this study was designed to detect a large treatment
effect (.40%) using an objective scale with good
repeatability (OCT). This translated into small number
of patients being required to attain the same degree of
statistical power. A statistically signiﬁcant treatment
effect was observed, whereas in some parameters, it
was marginal, considering the sample size, this indi-
cates a very large treatment effect. As with all clinical
trials, there is a low probability that these results have
occurred randomly, however, trials with small sample
sizes are more vulnerable to bias and random effects
than those with larger samples. These results should
therefore be veriﬁed at other centers, and separate
research groups.
In conclusion, this study aimed to validate the
hypothesis, deriving from our experimental preclinical
work, that MR antagonists inﬂuence SRF and choroid
thickness in CSC. Other studies are now required to
conﬁrm these results, to determine the optimal treat-
ment dose and duration, and to evaluate clinical factors
predicting response to MR antagonists. Other MR
antagonists, under development, and/or other routes of
administration could also be proposed for optimized
therapeutic index.
Key words: central serous chorioretinopathy, cho-
roidal thickness, choroidal vessels, mineralocorticoid
receptor, spironolactone, treatment.
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